Hoth Therapeutics, Inc.(HOTH) Tuesday reported positive interim data from its Phase 2a study dubbed CLEER-001, evaluating HT-001 for the treatment of pruritus associated with skin toxicities caused by Epidermal Growth Factor Receptor (EGFR) inhibitors.
EGFR inhibitors, widely used in oncology, commonly cause skin-related adverse effects, including intense itching.
In the CLEER-001 study, patients experienced a 50 percent reduction in pruritus severity, with mean scores dropping from 1.6 on Day 1 to 0.8 by Day 21. Rapid symptom relief was also observed, with mean scores improving to 1.0 by Day 7. Some patients achieved complete resolution of pruritus within the 21-day period. Further, HT-001 was well tolerated, and no treatment-related serious adverse events were reported.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.